Metadichol ® a novel nano lipid formulation that inhibits In Vitro, SARS-COV-2 and a multitude of pathological viruses

Palayakotai R Raghavan (raghavan@nanorxinc.com)  
Nanorx Inc

Keywords: Coronavirus, SARS-COV-2, COVID-19, ACE2, TMPRSS2, Furin, CD 147, VDR, Metadichol, Nano formulation, SARS, H1N1, Ebola, Zika

DOI: https://doi.org/10.21203/rs.3.rs-34021/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

New pathogenic virus outbreaks with increasing regularity are leading us to explore novel approaches, which will reduce the reliance on a time-consuming vaccine mode to halt the strike. The requirement is to find a universal approach to disarm any new and as yet unknown viruses as they appear. A promising approach could be by targeting the lipids membranes, common to all viruses and bacteria.

The ongoing pandemic of the SARS-coronavirus 2 (SARS-CoV-2) has restated the importance of interactions between components of the host cell plasma membrane and the virus envelope as a critical mechanism of infection. Metadichol®, a nano lipid emulsion, has been examined and shown to be a strong candidate to help stop the proliferation of the SARS-COV-2.

Naturally derived substances, such as Cyclodextrin and sterols, reduce the infectivity of various types of viruses, including the coronavirus like SARS-COV-2, by modifying the lipid-dependent attachment to human host cells. SARS-COV-2 uses the receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming.

Metadichol®, a nano lipid formulation of long-chain alcohols, has been shown to inhibit TMPRSS2 (EC50 of 96 ng/ml). Compared to the inhibitor Camostat Mesylate (26000 ng/ml), it is 270 times more potent. Also, Metadichol ® is a moderate inhibitor of ACE2 @ 31 µg/ml. In the SARS-COV2 anti-viral assay using CACO2 cells, it has an EC90 of 0.16 µg/ml.

Introduction

There is today an increasing need for a broad-spectrum antimicrobial agent, which could inactivate human pathogens such as bacteria and viruses. Rapid resistance has propelled this approach by microorganisms to focused drugs. The most recent trigger is the fear of a future pandemic caused by new, poorly studied virulent strains, like the present SARS-COV-2.

Background To Sars-cov-2

The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (COVID-19), is a pandemic 1, which has caused global havoc within a few months. To medically control a rapidly spreading viral pandemic utilizing specific Antivirals and vaccines will prove expensive, time-consuming, and carries with it compromise on the safety and efficacy. An alternative approach is to test molecules that are already proven safe and tested to be effective against SARS-COV-2. Among the candidates being tested are Camostat mesylate (a 35year Japanese drug) Avigan (another Japanese Drug) and Gilead Science Inc's Remdesivir 2.

To enter a host cell, the SARS COV-2 needs TMPRSS2 3, a serine protease, and ACE 2 4 to bind and thus facilitate its entry. Blocking both receptors can effectively stop the cell entry' mechanism used by the virus.

TMPRSS2 is a protease that primes the spike protein of SARS-CoV, and the Middle East respiratory syndrome-related coronavirus (MERS-CoV). Camostat mesylate (CM), an inhibitor of TMPRSS2, inhibited SARS-CoV in a mouse model 5,6 Hoffmann et al., 7 determined that the SARS-CoV-2 requires TMPRSS2. They showed that CM blocks the virus entry into lungs. So far there are no clinical data on the use of the CM in patients.
The other receptor used by viruses to gain entry into the host cell is ACE2. SARS-CoV-2 has a spike (S) protein on its viral envelope (exterior) that binds to the transmembrane protein angiotensin-converting enzyme 2 (ACE2), which is present in human cells. ACE2 protein is essential for viral entry. However, ACE2 also regulates blood pressure and blood volume; blocking this entirely would be detrimental. A solution that partially regulates ACE2 in concert with inhibition of TMPRSS2 would thus be an ideal solution.

Lipids and Viruses

Viral envelope lipid plays a role in both viral stability as well as its infective capabilities. For example, substances that affect the lipid envelop like Phospholipases, organics solvents, and surfactants like soaps have shown to affect the viral infectability. Causing envelope disintegration, they stop the virus transmission to a new host. Active ingredients in a number of the cleaning agents, wipes, and tissues target the viral lipid envelop to render the virions non-viable. Snipes and coworkers showed that saturated alcohols could inactivate viruses with chain lengths from 10 to 14 carbons. Their studies established that inactivation of enveloped viruses by lipids varies greatly, depending on both the nature of the lipid and the type of virus. Hilmarsson et al. studied the virucidal effects of medium and long-chain (8 to 18 carbon) fatty alcohols and corresponding lipids against HSV-1 and HSV-2 respiratory syncytial virus (RSV) and human virus type 2 (HPIV2) and enveloped viruses, at various concentrations, times and pH levels. After 10-minute incubation at 37 deg C and ten mM concentration, 14 of the lipids tested caused a 100 000-fold or more significant reduction in HSV titer. Testing between pH 7 and 4.2 showed that the pH to 4.2 caused a more rapid inactivation of HSV-1 virus titer in one minute. These long-chain alcohols may act by penetrating the envelope of the virus by hydrophobic effect, making it permeable to small molecules and thus inactivating the virus, the degree of penetration into lipid membranes due to the chain length of a lipid compared with the thickness of the membrane.

Metadichol is a nano lipid formulation of long chain alcohols. Metadichol has been shown to inhibit viruses in vitro and in vivo. Metadichol was tested for it inhibitory actions against ACE2, TMPRSS2 and anti-viral assay with SARS-COV-2.

Experimental Methods

All assays were on a fee for service contract basis and outsourced to Bioanalytical testing companies worldwide. Antiviral assay was done by a Bio Safety level 3 (BSL3) facility in USA.

Anti-Viral assay

Metadichol was serially diluted using eight half-log dilutions in test medium (MEM supplemented with 2% FBS and 50µg/mL gentamicin) so that the starting (high) test concentration was 100 µg/ml. Each dilution was added to 5 wells of a 96-well plate with 80-100% confluent CACO-2 cells.

Three wells of each dilution were inoculated with virus, with two wells uninoculated (as toxicity controls), six wells were inoculated and untreated (as virus controls), and six wells were uninoculated and untreated (as cell controls). SARS-CoV-2 virus was prepared to achieve the lowest possible multiplicity of infection (MOI) that would yield >80% cytopathic effect (CPE) within 5 days. M128533 (Protease inhibitor specific for SARS virus.) was tested in parallel as a positive control. Plates were incubated at 37±2°C, 5% CO2. On day 3 post-infection, once untreated virus control wells reached maximum CPE, plates were stained with neutral red dye for approximately 2 hours (±15
Supernatant dye was removed, and wells rinsed with PBS, and the incorporated dye was extracted in 50:50 Sorensen citrate buffer/ethanol for >30 minutes and the optical density was read on a spectrophotometer at 540 nm.

Optical densities were converted to percent of cell controls and the concentration of compound that would cause 50% cell death (CC50) in the absence of virus was calculated by regression analysis. The selective index (SI) is the CC50 divided by EC90. Results in Table 1

Table 1. In vitro antiviral results

|                     | CC50 | EC90 | SI90 |
|---------------------|------|------|------|
| Metadichol (µg/ml)  | 4    | 0.15 | 20   |
| M128533 (µg/ml)     | >10  | 0.2  | >33  |

EC90: Calculated concentration to reduce virus yield by 1 log (90%), SI = CC50/EC50

For virus yield reduction (VYR) assay, the supernatant fluid from each compound concentrations was collected on day 3 post infection, before neutral red staining (3 wells pooled) and tested for virus titer using a standard endpoint dilution CCID50 assay in Vero 76 cells and titer calculations using the Reed-Muench (1948) equation. The concentration of compound required to reduce virus yield by 1 log10 was calculated by regression analysis (EC90). The selective index (SI) is the CC50 divided by EC90.

Table 2. Shows Cytotoxicity and virus yield data for each concentration of Metadichol tested

| Metadichol Concentration Titer (µg/ml) | Cytotoxicity (%) | Virus Titer (CCID50 per 0.1 ml) |
|---------------------------------------|------------------|---------------------------------|
| 100                                   | 100%             | <0.7                            |
| 32                                    | 100%             | <0.7                            |
| 10                                    | 83%              | <0.7                            |
| 3.2                                   | 54%              | 0.7                             |
| 1                                     | 17%              | 4.3                             |
| 0.3                                   | 26%              | 1.5                             |
| 0.1                                   | 19%              | 5.7                             |
| 0.03                                  | 0%               | 5.3                             |
As shown in Table 2, the virus reduction assay did not follow a typical dose response, with virus reduction seen at concentration of 0.3 µg/ml and 3.2 µg/ml, but no reduction seen at a concentration of 1 µg/ml. Assuming that breakthrough of virus at 1 µg/ml was an outlier. The calculated SI ratio was 20 (Table 1), indicating EC 90 of 0.15 µg/ml.

**TMPRSS2 Inhibition assay**

Procedure

TMPRSS purified from LNCaP cells (Cayman Chemicals) was used as an enzyme source. The reaction mixture contains the purified TMPRSS2 protease in TBS buffer with or without a range of various concentrations from 1.56 to 100 ng/ml of test sample or inhibitor. The reaction mixture was incubated for 10 mins and at 37°C. To the reaction mixture, 1µl of 10mM fluorogenic trypsin substrate Cbz-Gly-Gly-Arg-AMC was added and the kinetic fluorescence reading was recorded after 2 mins incubation at 37°C at 383ex and 455em at 5-10 mins using Spectramax i3X, Molecular devices. Change in fluorescence (delta RFU) was calculated to determine the inhibitory effects of the test sample. Camostat mesylate at a two-fold range of concentrations from 1.56 to 100nM was used as a positive control for TMPRSS2 protease.

| Sample            | Concentration | RFU       | % Inhibition | IC 50        |
|-------------------|---------------|-----------|--------------|--------------|
| Control           | 0             | 43233358  | 0.00         |              |
| Metadichol (ng/ml)| 1.56          | 41305150  | 4.46         | 96.65 ng/ml  |
|                   | 3.12          | 39329385  | 9.03         |              |
|                   | 6.25          | 36713767  | 15.08        |              |
|                   | 12.5          | 33778222  | 21.87        |              |
|                   | 25            | 30695684  | 29.00        |              |
|                   | 50            | 26087008  | 39.66        |              |
|                   | 100           | 16009312  | 62.97        |              |
| Camostat mesylate (µg/ml) | 0.78 | 37984828 | 12.14 | 26.46 µg/ml |
|                   | 1.56          | 35235186  | 18.50        |              |
|                   | 3.125         | 31685728  | 26.71        |              |
|                   | 6.25          | 29234396  | 32.38        |              |
|                   | 12.5          | 23276839  | 46.16        |              |
|                   | 25            | 18931887  | 56.21        |              |
|                   | 50            | 8797988   | 79.65        |              |

**ACE2 Inhibition assay**

The ACE2 Inhibitor Screening Assay Kit, Catalog no 79923 (BPS biosciences, San Diego USA) was to measure the exopeptidase activity of ACE2 and inhibition by Metadichol and control inhibitor DX600. The inhibitory activity was measured based on the fluorescence emitted by the cleavage of the chromogenic substrate.

Procedure:
Enzyme (ACE2) stocks were prepared and from the supplied kit. 20µl of enzyme solution (0.5ng/µl) was added to all the wells designated for the assay. DX600, a potent ACE2 inhibitor

Table 4 ACE2 assay data

| Sample   | Concentration ug/ml | RFU          | % Inhibition | IC50 ug/ml |
|----------|---------------------|--------------|--------------|------------|
| Control  | 0                   | 308315546    | 0.00         |            |
| Metadichol | 0.125               | 290309918    | 5.84         | 30.15      |
|          | 0.25                | 260064163    | 15.65        |            |
|          | 0.5                 | 249149792    | 19.19        |            |
|          | 1                   | 240301136    | 22.06        |            |
|          | 10                  | 212275253    | 31.15        |            |
|          | 20                  | 187702504    | 39.12        |            |
|          | 40                  | 139821100    | 54.65        |            |
| DX600    | 0.0156              | 252855648    | 17.99        | 0.1627     |
|          | 0.031               | 231028864    | 25.07        |            |
|          | 0.0625              | 193810784    | 37.14        |            |
|          | 0.125               | 145881248    | 52.68        |            |
|          | 0.25                | 127485752    | 58.65        |            |
|          | 0.5                 | 111498760    | 63.84        |            |

was used as a positive control for ACE2 inhibition at various concentrations ranging from 40µg/ml was used. To each well consisting of enzyme solution, 5µl of inhibitor solutions was added to respective designated wells. The reaction mixture was incubated at room temperature for 5 mins. Post incubation, 25µl ACE2 substrate was added to the mixture and incubated for 1hr at room temperature. The RFU of cleavage of the substrate was read at Ex555nm and Em585nm using Spectramax i3x, Molecular devices. The IC50 values were calculated based on

**Discussion**

The results reported open the gateway to effective and safe therapies for COVID-19. Metadichol inhibits ACE2 sufficiently to prevent SARS-CoV-2 entry into host cells. and at the same time the concentrations for inhibition of viral passage is not high enough to affect physiological functions the host.

The results also demonstrate Metadichol's direct anti-viral effect against SARS-COV-2 virus itself, in CACO-2 cells with an EC90 of 0.15 µg/ml. Comparatively this result gives it a 2000 fold higher effectiveness than Remdesivir and 4000 fold potency over Hydroxy chloroquine phosphate. Metadichol also inhibits TMPRSS2, as is seen to be 270-fold more potent than Camostat Mesylate. Metadichol inhibits moderately ACE2 and, in combination with TMPRSS2 inhibition, likely leading to a pronounced synergistic effect in overcoming viral entry. The anti-viral assay shown in Table 8, suggest that it is toxic to cells at concentrations above 1 µg/ml. but Metadichol is not toxic as the LD 50 is 5000 mg/kilo. It is likely that Metadichol at higher concentrations behaves in a soap mimicking manner, by disrupting the lipid membrane and at lower concentrations it neutralizes the virus by a different mechanism. A previously published work (see ref 15) on anti-viral assay this same “toxicity” was seen and this is shown in Tables 5 and 6.
Raw data from Cytotoxicity of Metadichol without virus present in Vero cells as measured by Neutral red assay. When >75% “toxicity” occurred in the absence of virus, no viral CPE value was reported.

Table 5. Metadichol assay without virus present in Vero cells

| Units are ug/mL unless noted | Adenovirus | Tacaribe | Rift Valley | SARS | Japanese Encephalitis | West Nile virus | Yellow Fever | Powassan virus |
|-----------------------------|------------|----------|-------------|------|-----------------------|-----------------|--------------|---------------|
| ug/mL Metadichol            |            |          |             |      |                       |                 |              |               |
| 500                         | 95%        | 98%      | 96%         | 96%  | 100%                  | 100%            | 100%         | 100%          |
| 160                         | 92%        | 98%      | 96%         | 95%  | 100%                  | 100%            | 100%         | 100%          |
| 50                          | 90%        | 97%      | 97%         | 95%  | 100%                  | 100%            | 100%         | 100%          |
| 16                          | 85%        | 95%      | 81%         | 92%  | 88%                   | 77%             | 98%          | 100%          |
| 5                           | 0%         | 23%      | 26%         | 35%  | 33%                   | 28%             | 35%          | 44%           |
| 1.6                         | 0%         | 2%       | 10%         | 15%  | 12%                   | 14%             | 19%          | 6%            |
| 0.5                         | 0%         | 3%       | 9%          | 0%   | 2%                    | 3%              | 2%           | 0%            |
| 0.16                        | 0%         | 17%      | 3%          | 0%   | 0%                    | 0%              | 4%           | 0%            |
| CC50                        | 9.90       | 7.30     | 8.40        | 6.70 | 7.20                  | 8.50            | 5.00         | 5.1           |

Table 6. Metadichol vs Various viruses as measured by Neutral Red assay

| ug/mL Metadichol | Adenovirus | Tacaribe | Rift Valley Fever | SARS | Japanese Encephalitis | West Nile | Yellow Fever | Powassan |
|------------------|------------|----------|-------------------|------|-----------------------|-----------|--------------|---------|
| 5                | 100%       | 31%      | 100%              | 0%   | 56%                   | 84%       | 70%          | 53%     |
| 1.6              | 100%       | 69%      | 100%              | 52%  | 87%                   | 100%      | 73%          | 100%    |
| 0.5              | 100%       | 97%      | 100%              | 100% | 100%                  | 100%      | 95%          | 100%    |
| 0.16             | 100%       | 100%     | 100%              | 100% | 100%                  | 100%      | 96%          | 100%    |
| EC50             | >9.9       | 2.8      | >8.4              | 1.7  | >7.2                  | >8.5      | >5           | >5.1    |

It is not toxicity of Metadichol on cell lines but rather it behaves as a “detergent” in neutralizing the SARS-COV-2 and other pathogenic viruses as shown in Table 7.

Also, Metadichol® targets cancer cells in CACO-2 cells. In a previous study of Klotho gene expression of cancer cell lines Mia-Paca, Colo 205 and Panc1, where it was also seen to be toxic to cell lines above 1 µg/ml. It is also toxic to Leukemia CEM-SS cell lines above 5 µg/ml.

Table 7 List of Viruses Inhibited by Metadichol In Vitro
Vitamin D and SARS-COV-2 infection.

An out of control inflammatory response to SARS-COV-2 is the major cause of disease severity and death in patients with COVID-19 and is associated with high levels of circulating cytokines, TNF, CCl2, NF-KB, CRP, Ferritin. Metadichol (see Ref 14) is an inhibitor of CCl2 (also known as MCP-1), TNF, NF-κB, and CRP which, is a surrogate marker for cytokine storm and is associated with Vit D deficiency.

Vitamin D3 is generated in the skin through the action of UVB radiation, reaching 7-dehydrocholesterol in the skin, followed by a thermal reaction. Vitamin D3 is converted to 25(OH)D in the liver and then to 1,25(OH)2D (calcitriol) in the kidneys. Calcitriol binds to the nuclear vitamin D receptor, a DNA binding protein interacts with regulatory sequences near target genes that participate genetically and epigenetically in the transcriptional output of genes needed for functioning. Vitamin D reduces the risk of infections by mechanisms that include inducing cathelicidins and defensins resulting in lowered viral replication rates and reducing concentrations of pro-inflammatory cytokines. Supplementation with 4000 IU/d of vitamin D decreased dengue virus infection. Inflammatory cytokines increase in viral and bacterial infections, as seen in COVID-19 patients. Vitamin D can reduce the production of pro-inflammatory Th1 cytokines, such as tumor necrosis factor and interferon.

Vitamin D is a modulator of adaptive immunity and suppresses responses mediated by the T helper cell type 1 (Th1) by primarily repressing the production of inflammatory cytokines IL-2 and interferon-gamma (INF). Additionally, 1,25(OH)2D3 promotes cytokine production by the T helper type 2 (Th2) cells, which helps enhance the indirect suppression of Th1 cells by complementing this with actions mediated by a multitude of cell types.

1,25(OH)2D3 promotes the T regulatory cells' induction, thereby inhibiting inflammatory processes. It is known that COVID-19 infection is associated with the increased production of pro-inflammatory cytokines, C-reactive protein, increased risk of pneumonia, sepsis, acute respiratory distress syndrome, and heart failure. Case fatality rates (CFR's) in China were 6%-10% for those with cardiovascular disease, chronic respiratory tract disease, diabetes, and hypertension.

Telomerase and Viral infections

Metadichol increases h-TERT (telomerase) at one picogram by 16 fold. Viral infection puts a significant strain on the body. CD8 T cells that mediate adaptive immunity to protect the body from microbial invaders can easily
reach their Hayflick limit by depleting their telomeres. This is more so if telomeres are already short, then this is more likely to happen. Infections put enormous strain on immune cells to replicate. Naive T and B cells are particularly important when our bodies encounter new pathogens like the like COVID-19 coronavirus. The quantity of these cells is crucial for useful immune function.

**Aryl Hydrocarbon receptor and Viral Infections**

One of the major issues with infected COVID-19 patients has been a respiratory failure. It has been suggested that the Aryl Hydrocarbon receptor (AHR) is activated during coronavirus infections, impacting antiviral immunity, and lung cells associated with repair. NF-KB signaling via AHR may dampen the immune response against coronavirus. It has been reported that although some NF-KB signaling is needed for coronavirus replication, excessive activation of this pathway may be deleterious for the virus. AHR limits NF-kB activation and interferes with multiple antiviral immune mechanisms, including IFN-I production and intrinsic immunity. Yamada et al., suggested AHR (Constitutive aryl hydrocarbon receptor) signaling constrains type I interferon-mediated antiviral innate defense and suggested a need to block AHR constitutive activity and only an inverse agonist can dampen this. We have shown previously that Metadichol® binds to AHR as an inverse/protean agonist. Metadichol is an inverse/protean agonist (see Ref 14) of vitamin D receptor and thus can reduce complications attributed to out of control inflammation and cytokine storm.

Vitamin C and its role in viral infections

In infectious diseases, there is also a need to boost Innate and adaptive immunity. Micronutrients with the most robust evidence for immune support are vitamins C and D. Vitamin C is essential for a healthy and well functional host defense mechanism. The pharmacological application of vitamin C enhances immune function. Vitamin C has antiviral properties leading to inhibition of replication of herpes simplex virus type 1, poliovirus type 1, influenza virus type, and rabies virus in vitro.

Vitamin C deficiency reduces cellular and humoral immune responses, and treatment of healthy subjects promoted and enhanced natural killer cell activities underlining the immunological importance of vitamin C and supports its role as a crucial player in various aspects of immune cell functions, such as immune cell proliferation and differentiation, besides its anti-inflammatory properties. Moreover, the newly characterized hydroxylase enzymes, which regulate the activity of the hypoxia-inducible factors (HIF), gene transcription, and cell signaling of immune cells, need vitamin C as a cofactor for optimal activity.

Metadichol increases Vitamin C levels endogenously by recycling Vitamin C and reaches levels not reached by oral intake. The levels reached to bring about changes in improving diverse biomarkers.

Gene Cluster Network analysis.

The present drug discovery paradigm is based on the idea of one gene one target, one disease. It has become clear that it is hard to achieve single target specificity. Thus, a need to transition from targeting a single gene to multiple targeting of genes is likely to be more active, leading to blocking multiple paths of disease progression.

Table 8 COVID19 and 13 Curated genes
An analysis of the gene network analysis can provide a minimum set of genes that can form the basis for targeting diseases. This clustering network of genes can modulate gene pathways and biological networks. We used www.ctdbase.org 64 that has curated genes relevant to COVID-19.

Table 9 shows diseases impacted by the network of Curated genes.

| CCL2 | IL6 | IL7 |
|------|-----|-----|
| TNF  | TMPRSS2 | ACE2 |
| IL10 | CCL3 | AGT |
| IL2  | IL8 | IL2RA |
| CSF3 |     |     |
| Disease Name                        | Disease Categories                                      | P-value       | Corrected P-value | Annotated Genes Quantity | Annotated Genes                                                                 |
|------------------------------------|--------------------------------------------------------|---------------|-------------------|--------------------------|--------------------------------------------------------------------------------|
| COVID-19                           | Respiratory tract disease, Viral disease                | 4.49E-50      | 3.10E-47          | 13                       | ACE2, AGT, CCL2, CCL3, CSF3, CXCL10, IL10, IL2, IL2RA, IL6, IL7, TMPRS S2, TNF |
| Pneumonia, Viral                   | Respiratory tract disease, Viral disease                | 6.28E-49      | 4.34E-46          | 13                       | ACE2, AGT, CCL2, CCL3, CSF3, CXCL10, IL10, IL2, IL2RA, IL6, IL7, TMPRS S2, TNF |
| Coronaviridae Infections           | Viral disease                                           | 2.51E-47      | 1.74E-44          | 13                       | ACE2, AGT, CCL2, CCL3, CSF3, CXCL10, IL10, IL2, IL2RA, IL6, IL7, TMPRS S2, TNF |
| Coronavirus Infections             | Viral disease                                           | 2.51E-47      | 1.74E-44          | 13                       | ACE2, AGT, CCL2, CCL3, CSF3, CXCL10, IL10, IL2, IL2RA, IL6, IL7, TMPRS S2, TNF |
| Nidovirales Infections             | Viral disease                                           | 2.51E-47      | 1.74E-44          | 13                       | ACE2, AGT, CCL2, CCL3, CSF3, CXCL10, IL10, IL2, IL2RA, IL6, IL7, TMPRS S2, TNF |
| RNA Virus Infections               | Viral disease                                           | 7.12E-30      | 4.92E-27          | 13                       | ACE2, AGT, CCL2, CCL3, CSF3, CXCL10, IL10, IL2, IL2RA, IL6, IL7, TMPRS S2, TNF |
| Virus Diseases                     | Viral disease                                           | 2.51E-28      | 1.73E-25          | 13                       | ACE2, AGT, CCL2, CCL3, CSF3, CXCL10, IL10, IL2, IL2RA, IL6, IL7, TMPRS S2, TNF |
| Sexually Transmitted Diseases, Viral| Viral disease                                           | 1.99E-15      | 1.38E-12          | 7                        | CCL2, CCL3, IL10, IL2, IL2RA, IL6, TNF                                         |
| HIV Infections                     | Immune system disease, Viral disease                    | 2.26E-15      | 1.56E-12          | 7                        | CCL2, CCL3, IL10, IL2, IL2RA, IL6, TNF                                         |
| Lentivirus Infections              | Viral disease                                           | 2.26E-15      | 1.56E-12          | 7                        | CCL2, CCL3, IL10, IL2, IL2RA, IL6, TNF                                         |
| Retroviridae Infections            | Viral disease                                           | 2.26E-15      | 1.56E-12          | 7                        | CCL2, CCL3, IL10, IL2, IL2RA, IL6, TNF                                         |
| HIV Wasting Syndrome               | Immune system disease, Metabolic disease, Nutrition disorder, Viral disease | 5.79E-07      | 4.00E-04          | 2                        | IL6, TNF                                                                        |
| Coxsackievirus Infections          | Viral disease                                           | 1.45E-06      | 0.001             | 2                        | IL6, TNF                                                                        |
| Enterovirus Infections             | Viral disease                                           | 6.36E-06      | 0.0044            | 2                        | IL6, TNF                                                                        |
| Picornaviridae                     | Viral disease                                           | 7.52E-06      | 0.00519           | 2                        | IL6, TNF                                                                        |
Infections

We can filter the 13 genes to a set 4 genes: TNF, CCL2, ACE2 and TMPRSS2 are modulated by Metadichol and AGT that is part of RAS (Renin-Angiotensin System) network that ACE2 is part of (Figure 5).

A similar analysis of these network genes shows that they are closely networked in diseases with a highly significant p value. These five genes are closely related and the network can be generated as shown below (Figure 6) using www.innatedb.org. This integrates known interactions and pathways from major public databases.

| Disease Name                  | P-value | Corrected P-value | Genes | Annotated Genes                      |
|-------------------------------|---------|-------------------|-------|--------------------------------------|
| COVID-19                      | 1E-18   | 5.44E-16          | 5     | ACE2, AGT, CCL2, TMPRSS2, TNF       |
| Pneumonia, Viral              | 1.56E-18| 8.46E-16          | 5     | ACE2, AGT, CCL2, TMPRSS2, TNF       |
| Coronaviridae Infections      | 3.4E-18 | 1.85E-15          | 5     | ACE2, AGT, CCL2, TMPRSS2, TNF       |
| Coronavirus Infections        | 3.4E-18 | 1.85E-15          | 5     | ACE2, AGT, CCL2, TMPRSS2, TNF       |
| Nidovirales Infections        | 3.4E-18 | 1.85E-15          | 5     | ACE2, AGT, CCL2, TMPRSS2, TNF       |
| Pneumonia                     | 9.42E-15| 5.11E-12          | 5     | ACE2, AGT, CCL2, TMPRSS2, TNF       |
| Respiratory Tract Infections  | 3.13E-13| 1.7E-10           | 5     | ACE2, AGT, CCL2, TMPRSS2, TNF       |
| RNA Virus Infections          | 2.46E-12| 1.34E-09          | 5     | ACE2, AGT, CCL2, TMPRSS2, TNF       |
| Virus Diseases                | 9.48E-12| 5.15E-09          | 5     | ACE2, AGT, CCL2, TMPRSS2, TNF       |

The circled ones are circle in black. The highlighted ones are SIRT1, AR, and FOS. Gilinsk suggested that Vitamin D, as a potential mitigation agent in preventing SARS-COV-2 entry.

Metadichol binds to VDR, which controls the expression of FOS. AR also controls the expression of FOS as well as TMPRSS2. Based on these curated data expressions, Figure 7 was generated using web based software PACO shows the relationship between genes in the network. VDR controls FOS expression, FOS controls AGT, AGT controls expression of AGTR1 and ACE and AR controls expression of TMPRSS2. Goren et al. suggested that SARS-CoV-2 infection is likely to be androgen-mediated. The first step to infectivity is the priming of the spike proteins in SARS-COV-2 by transmembrane protease serine 2 (TMPRSS2), which also cleaves angiotensin-converting enzyme 2 (ACE2) for augmented viral entry. This is seen in the network (Fig 6) Sirt1, which plays an active role in enhancing immunity in viral infections.
Proteases like Furin and Adam-17 have been described to activate the spikes in vitro, for viral spread and pathogenesis in the infected hosts. The VDR controls Furin expression, mediated through its interaction with SRC. Adam-17 is regulated via CEPRP and CEBP73,74 which is involved in the regulation of genes involved in immune and inflammatory responses. Recently Ulrich and Pilalt75 proposed that CD147 is another receptor used as a viral entry like ACE2. CD147 is a known receptor76 for the parasite that causes Malaria in humans “plasmodium falciparum”. Interestingly, Metadichol (See Ref 6, US patent 9,006,292) inhibits the malarial parasite.

The key to entry into cells by SARS-COV-2 is ACE2 which, when endocytosed with SARS-CoV, results in a reduction of ACE2 on cells, and an increase of serum AngII77. AngII acts as a vasoconstrictor and a pro-inflammatory cytokine (Figure 8) via AT1R78. The AngII-AT1R axis also activates NF-κB79. SARS-CoV-2 infection in the lungs can activate NF-κB, which can activate the IL-6 increase, leading to multiple inflammatory and autoimmune diseases80.

The dysregulation of angiotensin downstream of ACE2 leads to cytokine release that is seen in COVID-19 patients, resulting in increases TNF that leads to IL6, CCI2, NF-KB, and CRP levels. The cytokine storm results in ARDS (Acute respiratory distress syndrome). Metadichol, by its binding to VDR, leads to a network of genes that are involved in mitigating entry and mitigating SARS-COV-2 infection via the Renin-Angiotensin pathway in Figure 8.

Clinical

A pilot study (outside the USA) on five COVID-19 patients with minor symptoms showed the absence of virus after 2-4 days of Metadichol @ 20 mg per day. To validate this further, we have been initiated a study in collaboration with the government agencies. We have expanded the trial on over 100 patients with Metadichol vs. comparable control groups, with only Standard Care. We hope to communicate these results very shortly.

Summary And Conclusions

Metadichol, as we have shown, blocks entry of ACE2, TMPRSS2, and CD147 through inhibiting malarial parasite and also Furin, whose expression is controlled by VDR. Metadichol is a unique nano lipid emulsion that inhibits many viruses. Metadichol’s81 action on multiple genes and proteins lead to over 2000 unique interactions with other genes and resulting in a network that affects many biomarkers and diseases, thereby helping bring about Homeostasis.

Metadichol is a safe, non-toxic product, made from renewable sources and commercially available for the last six years, with no reported side effects. This property allows for use of Metadichol in situation that exists today and also to prevent future occurrence of SARS-COV-2 infections being predicted and use to it will allow a rapid return to normal human activity world wide.

Glossary Of Gene Descriptions
| Gene          | description                                      |
|--------------|--------------------------------------------------|
| VDR          | vitamin D receptor                               |
| AHR          | aryl hydrocarbon receptor                        |
| TERT         | telomerase reverse transcriptase                 |
| KL           | klotho                                           |
| PAI1 (SERPINE1) | serpin family E member 1                        |
| HIF 1 alpha  | Hypoxia-inducible factor 1-alpha                 |
| CCL2         | C-C motif chemokine ligand 2                     |
| ICAM1        | intercellular adhesion molecule 1                |
| TNF          | tumor necrosis factor                            |
| ACE          | angiotensin I converting enzyme                  |
| ACE2         | angiotensin I converting enzyme 2                |
| AGTR1        | angiotensin II receptor type 1                   |
| AGTR2        | angiotensin II receptor type 2                   |
| TMPRSS2      | Transmembrane serine protease 2                  |
| SIRT1        | sirtuin 1                                        |
| TNF          | tumor necrosis factor                            |
| FURIN        | furin, paired basic amino acid cleaving enzyme   |
| CD 147 (BSG) | Basigin (BSG) also known as extracellular matrix metalloproteinase inducer |
| IL6          | interleukin 6                                    |
| IL10         | interleukin 10                                   |
| CCL3         | C-C motif chemokine ligand 3                     |
| IL2          | interleukin 2                                    |
| IL7          | interleukin 7                                    |
| CSF3         | colony stimulating factor 3                      |
| IL2RA        | interleukin 2 receptor subunit alpha             |
| CXCL8        | C-X-C motif chemokine ligand 8                   |

**Declarations**

**Competing interests:** The authors declare no competing interests.

**References**
1. Morse, J.S., et al 2020. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Chembiochem 21, 730-738.

2. Li, G and De Clercq, E., 2020 Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149-150.

3. Jerzy Janku, 2020. COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential therapeutics for SARS-CoV-2 coronavirus. UTJMS, 7, 1-6. https://orcid.org/0000-0003-2354-4046

4. I Hamming., et al 2007. The emerging role of ACE2 in physiology and diseases. J Pathol 212: 1–11

5. Rabaan A.A., 2017, Middle East respiratory syndrome coronavirus: five years later. Expert Rev Respir Med 11:901-912).

6. Zhou Y., et al 2015, Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 116:76-84.

7. Hoffmann M., et al. 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2. A clinically proven protease inhibitor blocks it. Cell 181:1-10.

8. Jane S Greatorex., et al. 2010, Effectiveness of Common Household Cleaning Agents in Reducing the Viability of Human Inuenza A/H1N1. Plos One, 5(2):e8987. DOI: 10.1371/journal.pone.0008987.

9. Snipes, W., . et al. 1977, Inactivation of lipid-containing viruses by long-chain alcohols. Antimicrob. Agents Chemother., 11, 98-104.

10. Hilmarsson, H., Kristmundsd´ottir, T., and Thormar, H. (2005). Virucidal activities of medium-and long-chain fatty alcohols, fatty acids, and monoglycerides against herpes simplex virus type 1 and 2: comparison at different pH levels. A.P.M.I.S., 113, 58-65.

11. Hilmarsson, H., et al, . 2006, Virucidal effects of lipids on visna virus, a lentivirus related to H.I.V. Arch. Virol., 151, 1217-1224;

12. Hilmarsson, H., Traustason, B.S., Kristmundsd´ottir, T. and Thormar, H. (2007) Virucidal activities of medium- and long-chain fatty alcohols and lipids against respiratory syncytial virus and para influenza virus type 2: comparison at different pH levels. Arch. Virol., 152, 2225-2236.

13. Saacs, C.E., Kim, K.S. and Thormar, H. (1994) Inactivation of enveloped viruses in human bodily fluids by purified lipids. Ann. N.Y. Acad. Sci., 724, 457-454.

14. P.R., U.S patents 8,722, 094 (2014) ; 9,034,383 (2015) ; 9,006,292(2015).

15. Raghavan, P.R., 2016, In vitro Inhibition of Zika Virus by Metadichol®. A Novel Nano Emulsion Lipid, J Immunol Tech Infect Dis 5:4; DOI: 10.4172/2329-9541.1000151

16. P.R., 2016, Inhibition of Dengue and other enveloped viruses by Metadichol®, a novel Nanoemulsion Lipid, Journal of the of Healing Outcomes, Vol 8, No 31,19-25.

17. Raghavan P.R., 2017, Inhibition of Viruses by Metadichol®: A Novel Nano Emulsion Lipid. Pediatric Infect Dis 1:35. DOI: 10.21767/2573-0282.100035

18. Jin, Z. et al. Structure of M pro from COVID-19 virus and discovery of its inhibitors. Nature, (2020). https://doi.org/10.1038/s41586-020-2223-y.

19. Yoshiharu Uno 2020, Camostat mesylate therapy for COVID-19Intern E. merg Med. Apr 29: 1-2. DOI: 10.1007/s11739-020-02345-9 [Epub ahead of print].

20. Aleman C.L., et al. A 12-month study of policosanol oral toxicity in Sprague Dawley rats. (1994) Toxicol Lett.; 70:77-87.
21. Aleman, C.L., et al. 1994, Carcinogenicity of policosanol in Sprague-Dawley rats: A 24-month study. Teratog Carcinog Mutagen: 14:239-49.

22. Aleman, C.L et al. 1995. Carcinogenicity of policosanol in mice: An 18-month study.

23. Raghavan P.R., 2018, Metadichol®, a Novel Agonist of the Anti-aging Klotho Gene in Cancer Cell Lines. J Cancer Sci Ther 10: 351-357.

24. P.R., (unpublished results).

25. Miriam Merad and Jerome C. Martin, 2020. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nature Reviews, Immunology volume 20, 355.

26. Ali Daneshkhah, et al., 2020. The Possible Role of Vitamin D in Suppressing Cytokine Storm and Associated Mortality in COVID-19 Patients. DOI: https://doi.org/10.1101/2020.04.08.20058578).

27. Pike, J.W, Christakos, S.2017. Biology, and Mechanisms of Action of the Vitamin D Hormone.Endocrinol. Metab.Clin 46, 815-818.

28. Liu PT., et al.2009, Convergence of IL-1 beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses.PLoS One 4(6):e5810.

29. Wang T.T., et al. 2004, Cutting edge; 1,25-dihydroxvitamin D3 is a direct inducer of antimicrobial peptide gene expression.J Immunol 173:2909-2912.

30. Martinez-Moreno., et al 2020. Effect of high doses of vitamin D supplementation on dengue virus replication, Toll-like receptor expression, and cytokine profiles on dendritic cells.Mol. Cell. Biochem 464, 169-181.

31. Charalampos Spilianakis, et al 2005 Twisting the Th1/Th2 immune response via the retinoid X receptor: Lessons from a genetic approach. Eur. J. Immunol. 2005. 35: 3400–3404, https://doi.org/10.1002/eji.200535588.

32. Ran Wei and Sylvia Christakos., 2015. Mechanisms Underlying the Regulation of Innate and Adaptive Immunity by Vitamin D, Nutrients.8251–8260. doi:3390/nu7105392

33. Cantorna, M.T., et al. 2015. Vitamin D and 1,25(O.H.)2D regulation of T cells.Nutrients 7, 3011-3020.

34. Cantorna, M.T. 2010. Mechanisms underlying the effect of vitamin D on the immune system.Proc. Nutr. Soc.69, 286-292.

35. Lemire, J.M., et al, 1985, 1,25-dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro.J. Immunol 134,3032€”

36. Huang, C.et al.2020 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet,VOLUME 395, ISSUE 10223, P497-506.

37. Wang, D et al., 2020 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.. 323(11):1061-1069.

38. Raghavan P.R., 2019, The Quest for Immortality. Introducing Metadichol®, a Novel Telomerase Activator. Stem Cell Res Ther 9: 446. DOI: 10.4172/2157-7633.1000446.

39. Nan-PingWeng., 2008, Telomere, and adaptive immunity Mechanisms of Ageing and DevelopmentVolume 129 pages 60-66.

40. Hodes RJ., et al 2002, Telomeres in T and B cells.Ä, Nat Rev Immunol 11(2):699-706.DOI:10.1038/nri890.

41. Poppe, M., et al 2017, NF-kappaB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells. PLoS Pathog 13, e1006286.
42. Giovannoni, F. et al. 2019, AHR. is a Zika virus host factor and a candidate target for antiviral therapy. Nat Neurosci 22, 729-740
43. Taisho Yamada., et al, 2016. Constitutive Aryl Hydrocarbon Receptor Signaling Constrains Type I Interferon-Mediated Antiviral Innate Defense Nature immunology 17, 687-694.
44. Raghavan P.R., 2017, Metadichol ®. A Novel Inverse Agonist of Aryl Hydrocarbon Receptor (A.H.R.) and NRF2 Inhibitor. J Cancer Sci Ther 9: 661-668. DOI:10.4172/1948-5956.1000489.
45. Heuser G, Vojdani A., 1997. Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: protein kinase-C. Immunopharmacol Immunotoxicol. ;19(3):291
46. Furuya A., et al 2008. Antiviral effects of ascorbic and dehydroascorbic acids in vitro. International Journal of molecular medicine.22(4):541-545.
47. Kim H, et al. 2016. Red ginseng and vitamin C increase immune cell activity and decrease lung inflammation induced by influenza A virus/H1N1 infection. Journal of Pharmacy and Pharmacology. 68(3):406-420.
48. Madhusudana S.N, et al 2004.In vitro inactivation of the rabies virus by ascorbic acid. International Journal of infectious diseases. 8(1):21
49. Alvares O., et al 1981, The effect of subclinical ascorbate deficiency on periodontal health in nonhuman primates. J Periodontal Res. 16(6):628
50. Goldschmidt M.C. et al, 1988. The effect of ascorbic acid deficiency on leukocyte phagocytosis and killing of actinomycyes viscosus. Int J Vitam Nutr Res. 58(3):326
51. Wintergerst E.S, Maggini S, Hornig D.H., 2006. Immune-enhancing role of vitamin C and zinc and effect on clinical conditions. Ann Nutr Metab.50(2):85
52. Woo A., et al.2010, Vitamin C acts indirectly to modulate isotype switching in mouse B cells. Anat Cell Biol.43(1):25
53. Carr A.C, Maggini S., 2017, Vitamin C, and Immune Function. Nutrients. 9(11),2111.
54. Levine M., et al, 1991. Ascorbic acid in human neutrophils. The American journal of clinical nutrition. 54(6 Suppl):1221S-1227S.
55. Kuiper,C,Vissers, M.C., 2014, Ascorbate as a cofactor for fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression. Front Oncol. 2014;4:359.
56. Loenarz C, Schofield C.J. 2011, Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem Sci.36(1):7-18.
57. Flashman E, et al., 2010, Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents. Biochem J.427(1):135-42.
58. Kuiper C., et al, 2014. Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response. Free Radic Biol Med. 69:308-17.
59. Raghavan P.R., 2018, Metadichol®, Vitamin C, and G.U.L.O. Gene Expression in Mouse Adipocytes. Biol Med (Aligarh) 10: 426. DOI 10.4172/0974-8369.1000426.
60. Raghavan P.R., 2017, Metadichol® and Vitamin C Increase In Vivo, an Open-Label Study. Vitam. Miner 6: 163.
61. Raghavan P.R (2017). Metadichol® Induced High Levels of Vitamin C: Case Studies. Vitam Miner 6: 169. DOI:10.4172/2376-1318.1000169
62. Creixell P, et al., Pathway, and network analysis of cancer genomes. Nat Methods. 2015;12(7):615.;
63. Barabasi A-L, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56.
64. Davis AP, et al,2018. The Comparative Toxicogenomics Database: update 2019. Nucleic Acids, Res. PMID:30247620.
65. Breuer et al,2013. In innate immunity and beyond - recent updates and continuing curation. Nucl. Acids Res. 41 (D1)
66. Gennadi V. Glinsky, 2020, Genomics-guided molecular maps of coronavirus targets in human cells: a path toward the repurposing of existing drugs to mitigate the pandemic. 1arXiv:2003.13665v1 [q-bio. G.N.] (pre-print pending peer review)
67. Mark B. Meyer., et al 2010. VDR/RXR and TCF4/β-catenin cistromes in Colonic Cells of Colorectal Tumor Origin: Impact on c-FOS and c-MYC Gene Expression Molecular Endocrinology, Volume 26, Issue 1, Page 37-51.
68. Igor Rodchenkov et al., 2020. Pathway Commons 2019 Update: integration, analysis, and exploration of pathway data. Nucleic Acids Research, Volume 48, Issue D1, Pages D489-D497,
69. Andy Goren, MD., et al 2020, .Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated J Am Acad Dermatolhttps://doi.org/10.1016/j.jaad.2020.04.032 (in press).
70. Zhenghong Lin, et al 2013. Sirt involvement in Virus-mediated diseases, JSM Microbiology 1(2):1006
71. Ma Y-C, et al. (2012). The Tyrosine Kinase c-Src Directly Mediates Growth Factor-Induced Notch-1 and Furin Interaction and Notch-1 Activation in Pancreatic Cancer Cells. PLoS ONE.7(3): e33414. https://doi.org/10.1371/journal.pone.0033414.
72. C Buitrago et al. 2001. Activation of Src Kinase in Skeletal Muscle Cells by 1, 1,25-(OH(2))-vitamin D(3) Correlates With Tyrosine Phosphorylation of the Vitamin D Receptor (V.D.R.) and VDR-Src Interaction. J Cell Biochem, 2;79(2):274-81.
73. Aleksandra Marchwicka, 2018. Regulation of Expression of C/EBPbetaGenes by Variably Expressed Vitamin D Receptor and Retinoic Acid Receptor Î± in Human Acute Myeloid Leukemia Cell Lines. Int J Mol Sci.19(7):1918.
74. Arcidiacono MV, Yang J, Fernandez E, et al.2015. The induction of C/EBPbeta contributes to vitamin D inhibition of A.D.A.M. 17 expression and parathyroid hyperplasia in kidney disease. Nephrol Dial Transplant. 30(3):423.
75. Henning Ulrich and Micheli M. Pillat ., 2020, CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement, Stem Cell Reviews and Reports 16:434–440.
76. Crosnier,C., et al. (2011). Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum.Nature, 480(7378), 534–537.https://doi.org/10.1038/nature10606
77. Keiji Kuba. 2005. crucial role of angiotensin-converting enzyme 2 (ACE2) in SARS coronavirus€”induced lung injury Nat Med 11, 875-879, https://doi.org/10.1038/nm1267.
78. S, et al,2018. Understanding Angiotensin II Type Receptor Signaling in Vascular Pathophysiology.Hypertension 71, 804-810.
79. Murakami, M., Kamimura, D., and Hirano, T.(2019). Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. Immunity 50, 812-831.
80. De Wit, E., et al. (2016). SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523-534.

81. https://www.researchgate.net/profile/Palayakotai_Raghavan/publications.

Figures

![Graph showing TMPRSS2 inhibition using Camostat mesylate](image)

**Figure 1**

Camostat mesylate

| Concentration (LogX) | Camostat mesylate |
|----------------------|-------------------|
| LogIC50              | 1.423             |
| IC50                 | 26.46             |
Figure 2
Metadichol

Figure 3
ACE2-assay Control
Figure 4

Metadichol

|                | Metadichol |
|----------------|------------|
| LogIC50        | 1.573      |
| IC50           | 37.39      |

Figure 5

Five genes and their network relationships
Figure 6

Network analysis of genes (Figure 5) involved in SARS-COV-2 Infections
Figure 7

Renin Angiotensin related genes and VDR related gene associations

Figure 8

Metadichol-VDR and modulation of RAS pathway